In a crowded oncology market, strategy-led storytelling, analytics-driven design, and sustainability-centered innovation are ...

ASCO® 2025 wasn’t only about oncology breakthroughs - it was also a showcase for how technology is redefining congress ...

This year’s ASCO® meeting spotlighted a bold shift in oncology: the possibility of curing metastatic disease. A new trial ...

Johnson & Johnson (J&J) has announced that it is seeking US Food and Drug Administration (FDA) approval to include new ...

Sanofi’s investigational multiple myeloma (MM) therapy has been granted orphan drug designation by the US Food and Drug ...

Botanical drugs are stepping into the space between traditional remedies and modern pharmaceuticals. These are not ...

With the changes at NHS England and the publishing of the 10-Year Plan, there is a lot of talk of change in the NHS in ...

Gilead Sciences’ Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) has been approved by the ...

Proactive protection This trend captures a universal human truth – when the world feels uncertain, we cling to what we can ...

The US Food and Drug Administration (FDA) has approved Apellis Pharmaceuticals’ Sobi-partnered Empaveli (pegcetacoplan) to ...

Espicom is a leader in business intelligence for the pharmaceutical and medtech sectors. Combining in-depth data and critical market analysis with the latest information technology, Espicom is the ...

Eli Lilly’s Alzheimer’s disease (AD) drug Kisunla ( donanemab) has demonstrated a growing benefit over three years in ...